Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
주식 순위 #12088
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
주가
$2.34
마지막 동기화: 2026-08-28
시가총액
$621.44M
변동 (1일)
-1.06%
변동 (1년)
55.67%
국가
GB
거래 Autolus Therapeutics plc (AUTL)

카테고리

Autolus Therapeutics plc (AUTL)의 주가 이력
최고 종가: $2.28 (2026-08-01 기준)

최저 종가: $26.43 (2018-06-01 기준)
Autolus Therapeutics plc의 주가 이력 (2018 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.20 -12.94%
AU
$138.18 473.58%
US
$759.27 7.20%
CH